Cue Biopharma, Inc. (CUE) Return on equity 2018–2025
Cue Biopharma, Inc. (CUE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-100.6%FY2025 · since FY2018: -114.7% → -100.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -100.6% | +131.8 pp |
| FY2024 | -232.4% | -95.6 pp |
| FY2023 | -136.8% | -56.1 pp |
| FY2022 | -80.7% | -13.3 pp |
| FY2021 | -67.4% | -10.7 pp |
| FY2020 | -56.8% | +10.5 pp |
| FY2019 | -67.2% | +47.5 pp |
| FY2018 | -114.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice